

Data Sharing Statement

Article Info	http://dx.doi.org/10.21037/cdt-20-328	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	miR-221 promotes PSMCs proliferation and migration by targeting TIMP3. miR-221 and TIMP3 could be potential therapeutic targets for the treatment of PAH.
4	Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Study protocol, statistical analysis plan, informed consent form, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since the technique or survival date may be updated over time.
7	To whom will you share the data?	Cardiologists who are interested in studies of pulmonary artery hypertension (PAH).
8	For what type of analysis or purpose?	For analysis to evaluate targeting miR-222 and TIMP3 as a potential therapy for pulmonary artery hypertension (PAH).
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: xinli3267_nj@hotmail.com.
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.